KURA - Kura Oncology: A Winner At ASH What To Expect In 2019
Shares of Kura Oncology (KURA) have risen by only 17% since my initial article highlighted early clinical results for lead drug candidate tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The stock has lost nearly 40% since my latest update piece and as an ROTY holding it fared poorly due to a disappointing performance at ESMO (European Society for Medical Oncology).
On the bright side, shares have rallied after encouraging data was presented at ASH (American Society of Hematology) annual meeting and it´s